Comparative Pharmacology of the 3 Marketed Dual Orexin Antagonists—Daridorexant, Lemborexant, and Suvorexant: Part 1: Pharmacokinetic Profiles
Sheldon Preskorn
Abstract
This first column in a 2-part series focuses on the pharmacokinetics of the 3 Food and Drug Administration-approved dual orexin receptor antagonists, daridorexant, lemborexant, and suvorexant, specifically as they relate to their use as sleep medications. Although other classes of sleep medications are not discussed, the same pharmacokinetic principles also apply to them.
Topics & Concepts
PharmacokineticsOrexin receptorPharmacologyFood and drug administrationMedicineOrexinReceptorInternal medicineNeuropeptideSleep and Wakefulness ResearchSleep and related disordersCircadian rhythm and melatonin